Resound Vivia 9 60S microRIE vs RxEars Rxi

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.

The RxEars Rxi is a budget-priced prescription hearing aid in an invisible-in-ear style, earning an A grade with a SoundScore of 4.1/5 in our lab testing. At $499, it represents one of the most affordable options in the prescription hearing aid category while still delivering solid overall performance. Speech clarity is a notable strength for this device. In quiet listening environments, the Rxi scores 4.3/5, which is 0.97 points above the category average—a strong result that should benefit users in conversational settings at home or in calm environments. Speech understanding in noisy conditions scores 2.1/5, slightly above the category average by 0.16 points, though this remains mixed in absolute terms and may present challenges in demanding acoustic situations like busy restaurants. Feedback handling is excellent at 4.7/5, essentially matching the category average and indicating reliable stability during daily wear. However, the Rxi shows notable limitations in other areas. Own-voice comfort scores 1.6/5, falling 1.15 points below the category average, which may result in a hollow or boomy perception of your own voice. Music streaming is not supported, scoring 0.0/5—a significant gap of 2.64 points below category average that buyers should consider if streaming audio matters to them. The RxEars Rxi is best suited for budget-conscious consumers who prioritize speech clarity in quieter environments and don't require streaming capabilities. Its invisible form factor and disposable battery design offer convenience, though those seeking better own-voice comfort or music features should explore alternatives.